Mabion's earnings have been declining at an average annual rate of -18.5%, while the Biotechs industry saw earnings growing at 17% annually. Revenues have been declining at an average rate of 3.3% per year.
Key information
-18.46%
Earnings growth rate
-16.42%
EPS growth rate
Biotechs Industry Growth
-14.59%
Revenue growth rate
-3.28%
Return on equity
-146.07%
Net Margin
-324.19%
Next Earnings Update
15 Sep 2026
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Mabion makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
DB:272 Revenue, expenses and earnings (PLN Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
18
-57
32
0
31 Dec 25
16
-63
34
0
30 Sep 25
15
-59
24
0
30 Jun 25
11
-65
32
0
31 Mar 25
38
-39
38
0
31 Dec 24
69
-6
42
1
30 Sep 24
111
10
53
2
30 Jun 24
140
37
49
3
31 Mar 24
146
42
42
5
31 Dec 23
152
41
40
6
30 Sep 23
148
58
39
8
30 Jun 23
157
42
35
14
31 Mar 23
165
32
31
15
31 Dec 22
164
23
29
15
30 Sep 22
156
45
34
8
30 Jun 22
117
34
34
9
31 Mar 22
75
26
32
8
31 Dec 21
36
2
30
14
30 Sep 21
2
-51
21
28
30 Jun 21
2
-45
20
24
31 Mar 21
0
-53
20
30
31 Dec 20
0
-56
19
34
30 Sep 20
0
-55
17
36
30 Jun 20
0
-63
18
40
31 Mar 20
0
-69
21
43
31 Dec 19
0
-64
21
41
30 Sep 19
0
-65
22
40
30 Jun 19
0
-59
21
39
31 Mar 19
0
-70
20
45
31 Dec 18
0
-69
20
45
30 Sep 18
0
-72
23
48
30 Jun 18
0
-74
23
49
31 Mar 18
0
-59
22
41
31 Dec 17
0
-58
21
43
30 Sep 17
0
-56
18
43
30 Jun 17
0
-57
16
47
31 Mar 17
0
-59
15
47
31 Dec 16
0
-56
13
44
30 Sep 16
0
-77
11
71
30 Jun 16
0
-65
9
59
31 Mar 16
3
-51
8
48
31 Dec 15
3
-43
5
40
30 Sep 15
3
-6
4
0
30 Jun 15
3
-5
3
0
Quality Earnings: 272 is currently unprofitable.
Growing Profit Margin: 272 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 272 is unprofitable, and losses have increased over the past 5 years at a rate of 18.5% per year.
Accelerating Growth: Unable to compare 272's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 272 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.2%).
Return on Equity
High ROE: 272 has a negative Return on Equity (-146.07%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/17 15:07
End of Day Share Price
2026/06/17 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mabion S.A. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.